Back to results
US 10,174,324 B2Granted
Treatment of Methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA
AssigneeCuRNA, Inc.
InventorsJoseph Collard, Olga Khorkova Sherman
Life of this patent
Estimating the term…
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Methionine Sulfoxide Reductase A (MSRA), in particular, by targeting natural antisense polynucleotides of Methionine Sulfoxide Reductase A (MSRA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MSRA.
Claims15
A synthetic, modified oligonucleotide of 10 to 30 nucleotides in length comprising at least one modification wherein the at least one modification is selected from:
- at least one modified sugar moiety;
- at least one modified internucleotide linkage;
- at least one modified nucleotide, and combinations thereof;
- wherein said oligonucleotide is an antisense compound which is at least about 90% complementary to and specifically hybridizes to a target nucleic acid sequence while avoiding non-specific binding to non-target nucleic acid sequences of a natural antisense polynucleotide of a Methionine Sulfoxide Reductase A (MSRA) gene wherein said natural antisense polynucleotide is not an mRNA of said MSRA gene, is selected from nucleotides 1380-3774 of SEQ ID NO:
- 2 and upregulates the function and/or expression of a Methionine Sulfoxide Reductase A (MSRA) gene in vivo or in vitro as compared to a normal control.
2 more elements
Dependencies are inferred from the claim text.